Summit Therapeutics (SUMM)
SUMM Share PerformanceMore
|52 week high||262.00 04/10/16|
|52 week low||88.00 16/09/16|
|52 week change||69.00 (63.40%)|
|4 week volume||368,536 01/06/17|
Media for (SUMM)
Presenter: Mark Wilcox
Presenter: Mark Wilcox
- 1 of 2
Latest News« previous» nextMore
22/06/2017 - 12:00 RNS
Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT PRESENTS DATA FROM PHASE 1 CLINICAL PROGRAMME OF EZUTROMID AT THE EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY CONGRESS Oxford, UK, 22 June 2017 - Summit Therapeu...
16/06/2017 - 15:44 Interactive Investor
Given UK political uncertainty, former AIM writer of the year Andrew Hore names companies exposed to overseas earnin...
15/06/2017 - 12:00 RNS
Summit Therapeutics to Participate in JMP Securities Life Sciences Conference Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 15 June 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development c...
14/06/2017 - 13:28 StockMarketWire
Summit Therapeutics has reported a loss for the three months ended 30 April 2017 of 4.8m, compared to a loss of 5.4m for ...
14/06/2017 - 12:00 RNS
Summit Therapeutics plc: 1st Quarter Results Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 AND OPERATIONAL PROGRESS Oxford, UK, 14 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug disc...
13/06/2017 - 14:59 StockMarketWire
Summit Therapeutics said it will announce its financial results for the first quarter ended 30 April on 14 June. At 2:59pm: (...
13/06/2017 - 12:00 RNS
Summit Therapeutics plc: Notice of Results Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 ON 14 JUNE 2017 Oxford, UK, 13 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development c...
05/06/2017 - 13:18 StockMarketWire
Summit Therapeutics has announced that the Company presented new preclinical data on ridinilazole were at ASM Micro...
|Dividend yield||0 %|
Latest discussion posts More
“The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...”▼
“"Weakening retail figures and the post-election uncertainty are not a great backdrop for UK-focused companies.The Conservatives have, at the moment, not completed a deal with ...”▼
“DMD drug trial update Q1 2018. Cdif drug Phase 3 to start Q1 2018. High cash burn. May get more up front from Sarepta 2017. DYOR”▼
Codes & Symbols
|Symbols||SUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM|